Search - tctmd.com

Displaying 161 - 180 of 298

Sort: Relevancy | Date

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

Todd Neale

October 04, 2019

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

Presentation TCT 2019

WATCHMAN: Device Characteristics, Procedural Technique, Clinical Outcomes, Ongoing Studies, and Evolution to WATCHMAN FLX

Presenter: Saibal Kar

September 26, 2019

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

Presentation TCT 2019

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

Presenter: Elizabeth Perpetua

September 25, 2019

News Daily News

VA Medical Centers’ Quality Measures for TAVR Pay Off

Caitlin E. Cox

August 30, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

Yael L. Maxwell

August 20, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Opinion Fellow Talk

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

Yashasvi Chugh, MD

August 05, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

Advertisement

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

WATCHMAN: Device Characteristics, Procedural Technique, Clinical Outcomes, Ongoing Studies, and Evolution to WATCHMAN FLX

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

VA Medical Centers’ Quality Measures for TAVR Pay Off

TCTMD’s Top 10 Most Popular Stories for August 2019

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

TCTMD’s Top 10 Most Popular Stories for July 2019

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content